Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

ite of Origin for GI Carcinoid Tumors 14Table 7:Diagnosis Tests for Different Types of Functioning Pancreatic Neuroendocrine Tumors 15Table 8:TNM Classification of Stomach Carcinoid Tumors 16Table 9:TNM Classification of Duodenum Carcinoid Tumors 17Table 10:TNM Staging of Appendiceal Carcinoid Tumors 17Table 11:TNM Classification of Pancreatic Neuroendocrine Tumors 18Table 12:TNM Staging for Pancreatic Neuroendocrine Tumors 18Table 13:Chemotherapy Regimens in GEP-NETs Carcinoma 22Table 14: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006–2011 25Table 15: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Market Forecast ($m), 2011-2019 28Table 16:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006–2011 29Table 17: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 30Table 18:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006–2011 31Table 19: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 32Table 20:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue($m), 2006–2011 33Table 21: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 34Table 22:Neuroendocrine Carcinoma Therapeutics Market,Germany, Revenue ($m), 2006–2011 35Table 23: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 36Table 24:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue($m), 2006–2011 37Table 25: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 38Table 26:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006–2011 39Table 27:Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m), 40Table 28:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006–2011 41Table 29: Neuroendocrine Carcinoma Therapeutics Market, Jap
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
(Date:5/4/2015)... May 4, 2015   Tocagen Inc. , ... data from Tocagen,s ongoing investigational studies were presented ... the American Association of Neurological Surgeons (AANS)/Congress of ... 1-2, 2015, in Washington, D.C. ... a meeting with FDA and continues to advance ...
(Date:5/1/2015)... Md. , May 1, 2015  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... the $28.5 million second tranche of a $40 million ... Woodford first invested $25 million in NW ... Woodford entered into an agreement with the Company for ...
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North ... it is the proud recipient of two Cisco® Partner Summit ... Partner of the Year and Security Partner of the Year ... conference taking place this week in Montreal ... one, but two Cisco partner awards at this year,s conference," ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2
... Professor Harry Dorn has developed a new area of fullerene ... semiconductors and quantum computing applications. , Dorn plays with ... are tinker toys. First, in 1999, he figured out how ... do it reliably, how to change the number of atoms ...
... (Nasdaq: PRXL ), a leading global biopharmaceutical ... the,first quarter of Fiscal Year 2009 (ending September ... conjunction with the successful completion of the,acquisition of ... Josef von Rickenbach, Chairman and Chief Executive Officer ...
... Annual Meeting, FREMONT, Calif., Sept. 8 Vermillion, ... today that a,team of scientists at Stanford University and ... the Annual General Meeting of the,PAD Coalition. Led by ... T.,Fung, Chief Scientific Officer at Vermillion, Inc., the research ...
Cached Biology Technology:Carbon molecule with a charge could be tomorrow's semiconductor 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 4PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 5Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 2Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 3
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... Nanoparticle films are no longer a delicate matter: Vanderbilt ... so they don,t disintegrate at the slightest touch. In ... to create nanoparticles ultrafine particles with diameters less than ... of different methods to mold them into thin films which ...
... that a new colon cancer screening technique created by ... it could potentially be as or more successful than ... technique uses optical technology, called low-coherence enhanced backscattering (LEBS) ... of the rectum. Light shines on the tissue, scatters, ...
... Sustainable Energy Technologies was chosen for multiple reasons: to ... change, to provide society with security of energy supply ... For this a European graduate school is thought to ... of thought, to foster the development of excellent young ...
Cached Biology News:Researchers create freestanding nanoparticle films without fillers 2Researchers create freestanding nanoparticle films without fillers 3Colon cancer screening technique shows continued promise in new study 2
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Prepared from plasminogen by activation with immobilized human uPA...
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Biology Products: